The firms, it was learnt, made many claims ranging from the outright cure for COVID-19 to the treatment of the symptoms. “So, we are now in the process of screening the 19 of them and we will shortlist some of them. “As you know, more than two months ago, we initiated the solidarity trial to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19. “On Friday, the Lancet published an observational study on hydroxycholoroquine and chloraquine and its effects on COVID-19 patients that have been hospitalised. “The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the solidarity trial, while the safety data is reviewed by the Data Safety Monitoring Board.

Source: Punch May 25, 2020 23:15 UTC